Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer

Journal of Pathology

Volumn 230, Issue 2, 2013, Pages 228-238

  Ronca, Roberto ^a   Alessi, Patrizia ^a   Coltrini, Daniela ^a   Di Salle, Emanuela ^a   Giacomini, Arianna ^a   Leali, Daria ^a   Corsini, Michela ^a   Belleri, Mirella ^a   Tobia, Chiara ^a   Garlanda, Cecilia ^b   Bonomi, Elisa ^a   Tardanico, Regina ^a   Vermi, William ^a,c   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

androgen; FGF; pentraxin; prostate cancer; tumour growth

Indexed keywords

ANDROSTANOLONE; FIBROBLAST GROWTH FACTOR; PENTRAXIN 3;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CELL STIMULATION; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MITOGENESIS; MOUSE; NEEDLE BIOPSY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TUMOR INVASION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CELL LINE, TUMOR; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DIHYDROTESTOSTERONE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MITOGENS; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; SERUM AMYLOID P-COMPONENT;

EID: 84877745098     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4181     Document Type: Article

References (63)

1. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nature Rev Cancer 2001; 1: 34-45.
2. Hsieh AC, Small EJ, Ryan CJ,. Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development. Lancet Oncol 2007; 8: 933-939.
3. Joly F, Tannock IF,. Chemotherapy for patients with hormone-refractory prostate cancer. Ann Oncol 2004; 15: 1582-1584.
4. Damber JE, Aus G,. Prostate cancer. Lancet 2008; 371: 1710-1721.
5. Itoh N, Ornitz DM,. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20: 563-569.
6. Johnson DE, Williams LT,. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60: 1-41.
7. Schwertfeger KL,. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets 2009; 10: 632-644.
8. Acevedo VD, Ittmann M, Spencer DM,. Paths of FGFR-driven tumorigenesis. Cell Cycle 2009; 8: 580-588.
9. Presta M, Dell'Era P, Mitola S, et al,. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-178.
10. Acevedo VD, Gangula RD, Freeman KW, et al,. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007; 12: 559-571.
11. Memarzadeh S, Xin L, Mulholland DJ, et al,. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 2007; 12: 572-585.
12. Maruyama-Takahashi K, Shimada N, Imada T, et al,. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions. Prostate 2008; 68: 640-650.
13. Mattila MM, Harkonen PL,. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev 2007; 18: 257-266.
14. Dayyani F, Gallick GE, Logothetis CJ, et al,. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011; 103: 1665-1675.
15. Garlanda C, Bottazzi B, Bastone A, et al,. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-366.
16. Presta M, Camozzi M, Salvatori G, et al,. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007; 11: 723-738.
17. Rusnati M, Camozzi M, Moroni E, et al,. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004; 104: 92-99.
18. Camozzi M, Rusnati M, Bugatti A, et al,. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 2006; 281: 22605-22613.
19. Leali D, Alessi P, Coltrini D, et al,. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides. Curr Pharm Des 2009; 15: 3577-3589.
20. Leali D, Bianchi R, Bugatti A, et al,. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived antiangiogenic pentapeptide. J Cell Mol Med 2010; 14: 2109-2121.
21. Leali D, Alessi P, Coltrini D, et al,. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. Mol Cancer Ther 2011; 10: 1600-1610.
22. Greenberg NM, DeMayo F, Finegold MJ, et al,. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995; 92: 3439-3443.
23. Polnaszek N, Kwabi-Addo B, Peterson LE, et al,. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003; 63: 5754-5760.
24. Foster BA, Kaplan PJ, Greenberg NM,. Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostatic Dis 1999; 2: 76-82.
25. Foster BA, Gingrich JR, Kwon ED, et al,. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57: 3325-3330.
26. Isacchi A, Statuto M, Chiesa R, et al,. A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity. Proc Natl Acad Sci U S A 1991; 88: 2628-2632.
27. Rivieccio V, Esposito A, Bellofiore P, et al,. High-level expression and efficient purification of recombinant human long pentraxin PTX3 in Chinese hamster ovary cells. Protein Expr Purif 2007; 51: 49-58.
28. Ronca R, Benzoni P, Leali D, et al,. Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1. Mol Cancer Ther 2010; 9: 3244-3253.
29. Noguchi S, Uchida N, Sato B, et al,. Growth control of androgen-dependent Shionogi carcinoma cells by growth factor(s) produced from androgen-independent Shionogi carcinoma cells in a paracrine mechanism. J Steroid Biochem 1989; 32: 479-483.
30. Knoll A, Schmidt S, Chapman M, et al,. A comparison of two controlled-release delivery systems for the delivery of amiloride to control angiogenesis. Microvasc Res 1999; 58: 1-9.
31. Ribatti D, Gualandris A, Bastaki M, et al,. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res 1997; 34: 455-463.
32. Euhus DM, Hudd C, LaRegina MC, et al,. Tumor measurement in the nude mouse. J Surg Oncol 1986; 31: 229-234.
33. Tomayko MM, Reynolds CP,. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24: 148-154.
34. Wee S, Gombotz WR,. Protein release from alginate matrices. Adv Drug Deliv Rev 1998; 31: 267-285.
35. Kwabi-Addo B, Ozen M, Ittmann M,. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004; 11: 709-724.
36. Mohammadi M, Froum S, Hamby JM, et al,. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998; 17: 5896-5904.
37. Doll JA, Reiher FK, Crawford SE, et al,. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001; 49: 293-305.
38. Liang G, Liu Z, Wu J, et al,. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012; 33: 531-541.
39. Rhodes DR, Yu J, Shanker K, et al,. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
40. Bostwick DG, Cheng L,. Precursors of prostate cancer. Histopathology 2012; 60: 4-27.
41. Song Z, Powell WC, Kasahara N, et al,. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res 2000; 60: 6730-6736.
42. Giri D, Ropiquet F, Ittmann M,. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999; 5: 1063-1071.
43. Dorkin TJ, Robinson MC, Marsh C, et al,. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999; 18: 2755-2761.
44. Udayakumar TS, Bair EL, Nagle RB, et al,. Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression. Mol Carcinog 2003; 38: 70-77.
45. Goldstein AS, Huang J, Guo C, et al,. Identification of a cell of origin for human prostate cancer. Science 2010; 329: 568-571.
46. Lawson DA, Zong Y, Memarzadeh S, et al,. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A 2010; 107: 2610-2615.
47. Ravenna L, Sale P, Di Vito M, et al,. Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. Prostate 2009; 69: 1245-1255.
48. Tafani M, Russo A, Di Vito M, et al,. Up-regulation of pro-inflammatory genes as adaptation to hypoxia in MCF-7 cells and in human mammary invasive carcinoma microenvironment. Cancer Sci 2010; 101: 1014-1023.
49. Wang JX, He YL, Zhu ST, et al,. Aberrant methylation of the 3q25 tumor suppressor gene PTX3 in human esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17: 4225-4230.
50. Leali D, Inforzato A, Ronca R, et al,. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis. Arterioscler Thromb Vasc Biol 2012; 32: 696-703.
51. Leali D, Bianchi R, Bugatti A, et al,. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide. J Cell Mol Med 2010; 14: 2109-2121.
52. Alessi P, Leali D, Camozzi M, et al,. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur Cytokine Netw 2009; 20: 225-234.
53. Beenken A, Mohammadi M,. The FGF family: biology, pathophysiology and therapy. Nature Rev Drug Discov 2009; 8: 235-253.
54. Lieu C, Heymach J, Overman M, et al,. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011; 17: 6130-6139.
55. Casanovas O, Hicklin DJ, Bergers G, et al,. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
56. Brower V., How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. J Natl Cancer Inst 2009; 101: 846-847.
57. Borgenstrom M, Jalkanen M, Salmivirta M,. Sulfated derivatives of Escherichia coli K5 polysaccharides as modulators of fibroblast growth factor signaling. J Biol Chem 2003; 278: 49882-49889.
58. Coltrini D, Di Salle E, Ronca R, et al,. Matrigel plug assay: evaluation of the angiogenic response by reverse transcription-quantitative PCR. Angiogenesis 2013; 16: 469-477.
59. Luo JH, Yu YP, Cieply K, et al,. Gene expression analysis of prostate cancers. Mol Carcinog 2002; 33: 25-35.
60. LaTulippe E, Satagopan J, Smith A, et al,. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62: 4499-4506.
61. Welsh JB, Sapinoso LM, Su AI, et al,. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001; 61: 5974-5978.
62. Wallace TA, Prueitt RL, Yi M, et al,. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008; 68: 927-936.
63. Singh D, Febbo PG, Ross K, et al,. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1: 203-209.